Articles tagged "Immunosuppression"

2019 American Transplant Congress
Antirejection Efficacy in De Novo Renal Transplant Recipients Receiving Everolimus with a Reduced-Exposure Calcineurin Inhibitor-Based Regimen: 24-Month Results from the TRANSFORM Study
H. Tedesco Silva¹, F. Citterio¹, M. Henry¹, T. R. Srinivas¹, Y. Watarai¹, S. Steinberg¹, N. Basic-Jukic¹, V. D. Garcia¹, E. Mor¹, V. R. Peddi¹, P. Narvekar², M. P. Hernandez Gutierrez², P. Bernhardt², J. Pascual¹
¹TRANSFORM Study Group, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
*Purpose: To compare the antirejection efficacy outcomes of an everolimus+reduced-exposure CNI (EVR+rCNI) vs mycophenolic acid+standard-exposure CNI (MPA+sCNI) regimen in renal transplant recipients (RTxRs) from the…
2019 American Transplant Congress
A Prospective Randomized Multicenter Trial (B E S T Trial) of Belatacept-Based C N I- and Corticosteroid-Free Immunosuppression: Final Two Year Results
D. B. Kaufman¹, A. R. Shields², J. P. Leone³, A. Wiseman⁴, A. J. Matas⁵, P. West-Thielke⁶, J. Lipscomb², E. King², R. R. Alloway⁷, E. S. Woodle for the BEST Study Group²
¹University of Wisconsin, Madison, WI, ²University of Cincinnati, Cincinnati, OH, ³Tampa General, Tampa, FL, ⁴University of Colorado School of Medicine, Denver, CO, ⁵University of Minnesota, Minneapolis, MN, ⁶University of Illinois, Chicago, Chicago, IL, ⁷University of Cincinnati, Cincinnati, WI
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal Trial) is a prospective, randomized, multi-center trial designed to compare two belatacept (BELA)-based calcineurin inhibitor-free (CNI), early…
2019 American Transplant Congress
Patient Centered AUC-Monitoring of Tacrolimus Using Capillary Microsampling
M. T. Gustavsen, K. Midtvedt, N. Vethe, S. Bergan, A. Åsberg
Oslo University Hospital, Rikshospitalet, Oslo, Norway
*Purpose: To reduce unwanted side effects of Tacrolimus (Tac), improvement of dosing is warranted. Therapeutic drug monitoring (TDM) of Tac based on trough concentrations (C0)…
2019 American Transplant Congress
Soluble C Type Lectin Receptor Protein Inhibition of Natural Killer Cell Mediated Tubular Epithelial Cell Death
S. Balaji¹, B. Fuhrmann², D. Lian³, H. Diao³, S. Ma³, Z. Zhang³, A. M. Jevnikar³
¹Physiology, Western University, London, ON, Canada, ²Microbiology and Immunology, Western University, London, ON, Canada, ³London Health Sciences Centre, London, ON, Canada
*Purpose: We have previously shown that Natural Killer (NK) cells can mediate kidney tubular epithelial cell (TEC) death and kidney ischemia-reperfusion injury (IRI) as well…
2019 American Transplant Congress
Clinical Implications of Belatacept Conversion in a High-Risk, Urban Renal Transplant Population
B. Valdepenas, J. Benken, E. Benedetti, Z. Hajjiri, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: Conversion to belatacept as maintenance immunosuppression has gained traction to prevent calcineurin inhibitor (CNI) induced toxicities in renal transplant (RTx) recipients. However, limited knowledge…
2019 American Transplant Congress
Risk Factors for Initial Sub- and Supra-Therapeutic Tacrolimus Trough Levels in Renal Transplant Recipients
M. Kapugi, K. Cunningham, C. D'Agostino, C. Kane, A. Novak, J. Schulte
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Sub-therapeutic tacrolimus trough levels have been associated with increased risk of rejection in renal transplant recipients and supra-therapeutic levels with infectious risks and drug…
2019 American Transplant Congress
Thymoglobulin Versus Alemtuzumab Induction in High Immunologic Risk Kidney Transplants
J. Lockridge¹, J. Pryor¹, D. Norman¹, A. Olyaei²
¹OHSU, Portland, OR, ²Pharmacy, OHSU, Portland, OR
*Purpose: The optimal induction immunosuppressive therapy to prevent kidney transplant rejection remains controversial, specifically among high immunologic risk patients. Our aim was to compare the…
2019 American Transplant Congress
Effects of Thalidomide and Dexamethasone Co-Treatment on CD8⁺ T Cells
J. Kim¹, E. Kim², Y. Cho¹, H. Lee¹, M. Kim³, Y. Kim³, K. Huh³, B. Kim⁴
¹The Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Korea, Republic of, ²Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea, Republic of, ³Department of Transplantation Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of, ⁴Nephrology Division, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
*Purpose: Thalidomide (TM) is known to have anti-cancer and anti-inflammatory effects and dexamethasone (DX) has been reported that it also reduces inflammation and inhibits inflammatory…
2019 American Transplant Congress
Clinical Outcomes of Using mTOR Inhibitors with Reduced Dose of Calcineurin Inhibitors in Lung Transplant Recipients: A Single Center Experience
M. Frawley¹, J. Leedy¹, A. James¹, A. Salter¹, V. Rusanov²
¹Department of Pharmacy, UAB Hospital, Birmingham, AL, ²Division of Pulmonary, Allergy, and Critical Care Medicine, UAB Hospital, Birmingham, AL
*Purpose: The use of mammalian target of rapamycin inhibitors (mTORi) in cardiothoracic transplantation has significantly increased over the past decade. Several recent clinical trials have…
2019 American Transplant Congress
Gut Microbiota May Affect a Variability of Tacrolimus Trough Levels in Kidney Transplant Recipients
J. Kim¹, H. Cho², J. Park³, M. Kwak⁴, B. Kim⁴, J. Lee⁵, D. Kim¹, B. Kim⁶, Y. Kim¹, H. Lee¹
¹Seoul National University Hospital, Seoul, Korea, Republic of, ²Chungbuk National University Hospital, Cheongju, Korea, Republic of, ³Kangwon National University Hospital, Chuncheon, Korea, Republic of, ⁴Chunlab Inc., Seoul, Korea, Republic of, ⁵Seoul National University Boramae Hospital, Seoul, Korea, Republic of, ⁶Hallym University, Chuncheon, Korea, Republic of
*Purpose: The gut microbiota alters expression of drug-metabolizing enzymes and transporters, and consequently affects therapeutic dose and response of medicines. We aimed to investigate the…